Skip to main content

Table 2 SETBP1 mutations in juvenile myelomonocytic leukemia

From: SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome

Reference Number of Patients Mutation Prevalence Impact on Survival
[46] 92 7 (7.6%) Yes* (p-NR)
[47] 42 2 (4.8%) NR
[48] 66 23 (24.8%) No (p-0.258 – Univariate)
Yes (p-0.026 – Multivariate)
[49] 70 7 (10%) Yes (p-0.03)
  1. NR Not reported; * Survival analysis was done in patients harboring SETBP1 or JAK3 mutations compared to patients without either mutation
Back to article page